Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro

Journal of Microbiological Methods

Volumn 57, Issue 1, 2004, Pages 107-114

  Tunney, Michael M ^a   Scott, Eileen M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibiotic synergy; Breakpoint sensitivity testing; Ceftazidime; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; IN VITRO STUDY; LABORATORY TEST; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA COMPLEX; CEFTAZIDIME; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

BURKHOLDERIA; BURKHOLDERIA CEPACIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 1542315371     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2003.12.001     Document Type: Article

References (18)

1. Aaron S.D., Ferris W., Henry D.A., Speert D.P., MacDonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161:2000;1206-1212.
2. Andrews J.M. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(Suppl. 1):2001;5-16.
3. Baltch A.L., Bassey C., Hammer M.C., Smith R.P., Conroy J.V., Michelsen P.B. Synergy with cefsulodin or piperacillin and three aminoglycosides or aztreonam against aminoglycoside resistant strains of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 27:1991;801-808.
4. Bosso J.A., Saxon B.A., Matsen J.M. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob. Agents Chemother. 34:1990;487-488.
5. Cappelletty D.M., Rybak M.J. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:1996;677-683.
6. Chin N.X., Neu H.C. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia. Diagn. Microbiol. Infect. Dis. 12:1989;343-349.
7. den Hollander J.G., Horrevorts A.M., van Goor M.L., Verbrugh H.A., Mouton J.W. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 41:1997;95-100.
8. Lang B.J., Aaron S.D., Ferris W., Hebert P.C., MacDonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 162:2000;2241-2245.
9. MacGowan A.P., Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48(Suppl. 1):2001;17-28.
10. Madaras-Kelly K.J., Moody J., Larsson A., Baeker H.L., Rotschafer J.C. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa. Chemotherapy. 43:1997;108-117.
11. McLaughlin F.J., Matthews W.J., Strieder D.J., Sullivan B., Taneja A., Murphy P., Goldmann D.A. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J. Infect. Dis. 147:1983;559-567.
12. Shawar R.M., MacLeod D.L., Garber R.L., Burns J.L., Stapp J.R., Clausen C.R., Tanaka S.K. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:1999;2877-2880.
13. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 123:2003;1495-1502.
14. Taccetti G., Campana S., Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian group for cystic fibrosis microbiology. Eur. J. Epidemiol. 15:1999;85-88.
15. Visalli M.A., Bajaksouzian S., Jacobs M.R., Appelbaum P.C. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1997;1475-1481.
16. Weiss K., Lapointe J.R. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;2411-2414.
17. White R.L., Burgess D.S., Manduru M., Bosso J.A. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40:1996;1914-1918.
18. Wu Y.L., Scott E.M., Po A.L., Tariq V.N. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:1999;389-392.